TLSI
NASDAQ · Biotechnology
Trisalus Life Sciences Inc
$3.71
-0.14 (-3.64%)
Open$3.87
Previous Close$3.85
Day High$3.91
Day Low$3.61
52W High$7.95
52W Low$3.42
Volume—
Avg Volume293.5K
Market Cap285.30M
P/E Ratio—
EPS$-1.23
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+16.7% upside
Current
$3.71
$3.71
Target
$4.33
$4.33
$2.61
$4.33 avg
$5.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 73.50M | 47.23M | 45.65M |
| Net Income | -75,032,336 | -3,256,844 | -3,940,718 |
| Profit Margin | -102.1% | -6.9% | -8.6% |
| EBITDA | -66,447,994 | -4,196,050 | -4,663,249 |
| Free Cash Flow | — | -5,024,799 | -4,621,021 |
| Rev Growth | — | +7.1% | +0.6% |
| Debt/Equity | 0.20 | 1.07 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |